Physician profile
Suparna Thind
NPI 1861838302
$1,247.75
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2020: $118 · 2021: $66.82 · 2022: $506 · 2023: $197 · 2024: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $302 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $301.50 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $497.18 | 2019-2024 | Lokelma, Farxiga |
| Akebia Therapeutics INC | $148.49 | 2022-2024 | Vafseo, Auryxia |
| Amgen INC. | $116.01 | 2019 | |
| Horizon Therapeutics Plc | $75.16 | 2021-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $68.42 | 2022-2024 | |
| Baxter Healthcare | $65.08 | 2022 | |
| Aurinia Pharma U.S., INC. | $61.02 | 2022-2023 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $34.73 | 2021-2023 | Ultomiris |
| Otsuka America Pharmaceutical, INC. | $34.19 | 2021-2022 | |
| Travere Therapeutics, INC. | $22.73 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.51 | 2024 | Jardiance |
| Mallinckrodt Hospital Products INC. | $20.96 | 2023 | Acthar |
| Glaxosmithkline, LLC. | $18.61 | 2023 | Benlysta |
| Ardelyx, INC. | $17.03 | 2024 | Ibsrela |
| Daiichi Sankyo INC. | $16.10 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $16.00 | 2022 | |
| Calliditas Therapeutics US INC. | $13.53 | 2023 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suparna Thind listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.